All News

2021,year

2021 Rheumatology Year in Review

d Jack Cush, MD

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
pill pillbox adherence

Comorbidities Drive Risk of Severe Outcomes with COVID-19

d Jack Cush, MD

The current edition of the MMWR from the CDC shows that among those vaccinated against COVID-19, there is a low risk of severe outcomes (hospitalization and death); the highest risk is seen in those with multiple comorbidities.

Read Article
URI.infection.COrona.jpg

COVID Breakthrough Infections with Arthritis and HIV

d MedPage Today

Among immunocompromised individuals vaccinated against COVID-19, solid organ transplant recipients as well as those with HIV and rheumatoid arthritis (RA) were significantly more likely to experience breakthrough infections versus people without immune dysfunction, a retrospective study found.

Read Article
covid coronavirus virus

New Onset Rheumatic Disorders with COVID-19 Infection

d Jack Cush, MD

The journal Cells has published a review of new rheumatic disorders following COVID-19 infection. Rheumatologists have infrequently noted such events and wondered what is the true incidence or range of possible manifestations.

Read Article
NICE (UK) has recommended upadacitinib for use in active Psoriatic Arthritis, 15 mg qd +/- MTX, in pts not responding to DMARDS. UPA can now be used in England Wales and Scotland https://t.co/JFxMrgjrUe

Links:

Dr. John Cush RheumNow ( View Tweet)

The global rheumatoid arthritis drugs market size was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027. https://t.co/hQTDc0ajdN

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Comorbidities Drive Risk of Severe Outcomes with COVID-19 https://t.co/9GgfvgnMke https://t.co/JGHp0mVPpF

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Study of biologic/ts DMARD switching in 8,398 axial spondyloarthritis pts from 5 Nordic registries showed a low rate of multiple switches (refractory?) over 3 years; ≥3 DMARDs (8%), ≥4 (3%) & ≥ 5 (1%); more w/ women, comorbiditiy & psoriasis https://t.co/tc5D3Bwnnj

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Cosentyx (secukinumab) was FDA approved for use in pediatric psoriatic arthritis & enthesitis-related arthritis, based on results of the ph III JUNIPERA study. Dosing based on weight (SEC 75 mg sc if 15-50kg; SEC 150 mg sc if 50 kg or more) https://t.co/S6mQmwKT1X

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Clinical Practice Guidelines for Multisystem Inflammatory Syndrome in Children Multisystem inflammatory syndrome in children (MIS-C) is new and serious complication of COVID-19 that preferentially affects adolescents. Read more : https://t.co/OAPdLCxHgy https://t.co/0RnYKeg891

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: New Onset Rheumatic Disorders with COVID-19 Infection The journal Cells has published a review of new rheumatic disorders following COVID-19 infection. Read more: https://t.co/X2DLznJynL https://t.co/wLCWt7gwgf

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Infectious mimics of #RA include viruses (Parvo B19, HBV, HCV, HIV, Chikungunya alphaviruses) mycobacterial infections (Poncet's dz, TB, leprosy), bacterial arthritis, brucellosis and Lyme disease. https://t.co/3FOydnsj1V

Links:

Dr. John Cush RheumNow ( View Tweet)

In case you missed it… Autoantibody Associations in Systemic Sclerosis https://t.co/sOe4A8OzQp https://t.co/jjYBVH05Iy

Links:

Dr. John Cush RheumNow ( View Tweet)
Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit! https://t.co/cb787PiX5v https://t.co/ChAqBRCh7c

Links:

Dr. John Cush RheumNow ( View Tweet)
Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 at the ACR21 Virtual meeting. https://t.co/MZroMY2rrb https://t.co/2Ey1hG4mv6

Links:

Dr. John Cush RheumNow ( View Tweet)
New Onset Rheumatic Disorders with COVID-19 Infection The journal Cells has published a review of new rheumatic disorders following COVID-19 infection. Read more: https://t.co/WdtNQWnGmk https://t.co/Fmoh1Wsvg4

Links:

Dr. John Cush RheumNow ( View Tweet)
Risk of Cancer w/ IgG4-related disease (IgG4-RD)? A meta-analysis of 10 studies shows compared to gen population, IgG4-RD has a higher risk of overall cancer(SIR 2.57), esp pancreatic (SIR 4.1) & lymphoma (SIR 69.2); but not lung or gastric cancer https://t.co/EzgMXIdFcL

Links:

Dr. John Cush RheumNow ( View Tweet)

MMWR (CDC) reports that In 2019, 12.3% and 10.0% of adults met fruit and vegetable intake recommendations. Fruit intake highest w/ Hispanics(16%), lowest in males (10%). Veggie intake highest ≥51 yrs (12%), lowest w/ low income (7%)https://t.co/fxQszBy7vO

Links:

Dr. John Cush RheumNow ( View Tweet)

Clinical Practice Guidelines for Multisystem Inflammatory Syndrome in Children Multisystem inflammatory syndrome in children (MIS-C) is new and serious complication of COVID-19 that preferentially affects adolescents. Read more : https://t.co/3VXU7vEkb7 https://t.co/bWUseG9ogf

Links:

Dr. John Cush RheumNow ( View Tweet)
Infectious mimics of #RA include viruses (Parvo B19, HBV, HCV, HIV, Chikungunya alphaviruses) mycobacterial infections (Poncet's dz, TB, leprosy), bacterial arthritis, brucellosis and Lyme disease. https://t.co/COjPWU8sC5

Links:

Dr. John Cush RheumNow ( View Tweet)

×